Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Gains from Sales and Divestitures: 2021-2025

Historic Gains from Sales and Divestitures for Aytu Biopharma (AYTU) over the last 5 years, with Jun 2025 value amounting to $11,193.

  • Aytu Biopharma's Gains from Sales and Divestitures fell 72.69% to $1,618 in Q3 2025 from the same period last year, while for Sep 2025 it was $1,618, marking a year-over-year decrease of 72.69%. This contributed to the annual value of $11,193 for FY2025, which is 56.90% down from last year.
  • According to the latest figures from FY2025, Aytu Biopharma's Gains from Sales and Divestitures is $11,193, which was down 56.90% from $25,971 recorded in FY2024.
  • Over the past 5 years, Aytu Biopharma's Gains from Sales and Divestitures peaked at $642,696 during FY2022, and registered a low of $11,193 during FY2025.
  • For the 3-year period, Aytu Biopharma's Gains from Sales and Divestitures averaged around $26,533, with its median value being $25,971 (2024).
  • Per our database at Business Quant, Aytu Biopharma's Gains from Sales and Divestitures surged by 300.18% in 2022 and then tumbled by 93.40% in 2023.
  • Over the past 5 years, Aytu Biopharma's Gains from Sales and Divestitures (Yearly) stood at $160,602 in 2021, then skyrocketed by 300.18% to $642,696 in 2022, then tumbled by 93.40% to $42,434 in 2023, then crashed by 38.80% to $25,971 in 2024, then tumbled by 56.90% to $11,193 in 2025.